<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686647</url>
  </required_header>
  <id_info>
    <org_study_id>ASC-ST1210</org_study_id>
    <nct_id>NCT00686647</nct_id>
  </id_info>
  <brief_title>AngioSculpt® Coronary Bifurcation Study</brief_title>
  <acronym>AGILITY</acronym>
  <official_title>AngioSculpt® Scoring Balloon Catheter Multi-Center Coronary Bifurcation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AngioScore, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AngioScore, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a new angioplasty catheter, AngioSculpt® for the
      treatment of bifurcation lesions (blockages occurring at branch points) in coronary arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Bifurcation lesions, which consist of a narrowing occurring at branch points of
      coronary arteries, typically involve both the main branch (parent vessel) and an adjacent
      side branch. These lesions pose a particularly challenging situation for angioplasty
      procedures due to the difficulty of covering both branches with stents and a higher rate of
      recurrence (restenosis). A new angioplasty scoring balloon catheter (AngioSculpt®) has
      recently been approved for the treatment of narrowings in coronary arteries. The AngioSculpt®
      catheter incorporates a nitinol device that consists of spiral wires that wrap around the
      balloon catheter. As the balloon inflates, the spiral wires score the lesion allowing the
      balloon to be more stable (avoid slippage) and may enlarge the narrowed sections of the
      artery with less pressure or risk of dissection (uncontrolled tearing of the inner lining of
      the artery wall commonly seen with conventional balloons).

      Study Purpose: To demonstrate the safety and efficacy of the AngioSculpt® used in conjunction
      with coronary stents (implantable wire mesh tubes for scaffolding blocked arteries) for the
      treatment of coronary artery bifurcation narrowings and to compare these results with the
      historical outcomes associated with the use of conventional balloons and stents in the
      treatment of bifurcation lesions.

      Study Design: A prospective, multi-center, non-randomized, single-arm study with results
      compared to a literature search derived historical control for conventional balloon
      angioplasty (OPC - Objective Performance Criteria). The intent of this study is to enroll and
      treat 100 patients at 8 U.S. interventional cardiology programs with clinical follow-up
      planned at 30 days and 9 months following the procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>1 day</time_frame>
    <description>Defined as less than or equal to 30% diameter stenosis in the main branch and less than or equal to 70% diameter stenosis in the side branch at the conclusion of the procedure (including adjunctive stenting) in the absence of in-hospital major adverse cardiac events (MACE) [cardiac death, myocardial infarction (MI), or target lesion revascularization (TLR]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiovascular Events</measure>
    <time_frame>30 days</time_frame>
    <description>cardiac death, myocardial infarction, or target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>9 months</time_frame>
    <description>cardiac death, myocardial infarction, or target lesion revascularization</description>
  </secondary_outcome>
  <enrollment type="Actual">93</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AngioSculpt® Scoring Balloon Catheter</intervention_name>
    <description>Use of a stent for the main branch of a bifurcation lesion and use of a scoring balloon for the side branch of the same bifurcation lesion</description>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AngioSculpt Scoring Balloon Catheter</intervention_name>
    <description>Treatment of the side-branch vessel of true bifurcation lesions using the AngioSculpt device</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age and able to give informed consent.

          -  Patients with significant (&gt; 50% diameter stenosis) native coronary artery disease
             involving a bifurcation and the ostium of the side branch vessel (Medina class (x, x,
             1)) including stable or unstable angina and silent ischemia.

          -  Patients with lesions suitable for percutaneous coronary intervention (PCI).

        Exclusion Criteria:

          -  Concomitant use of Rotablator, Cutting Balloon, or investigational coronary devices.

          -  Additional planned coronary interventions for a non-target lesion within 9 months of
             the study procedure.

          -  Left ventricular ejection fraction &lt; 35%

          -  Patients refusing or not candidates for emergency coronary artery bypass grafting
             (CABG)surgery

          -  Uncontrolled severe hypertension (systolic BP &gt;180 mm Hg or diastolic BP &gt;110 mm Hg)

          -  Patients who are not candidates for chronic treatment with aspirin or
             Clopidogrel/Ticlopidine

          -  Severe renal failure with creatinine &gt;2.0 mg/dL

          -  Untreated pre-procedural hemoglobin &lt;10 g/dL

          -  Coagulopathy manifested by platelet count &lt;100,000 or International Normalized ratio
             (INR) &gt;2.0 (INR is only required in patients who have taken warfarin within 2 weeks of
             enrollment)

          -  Women who are known or suspected to be pregnant

          -  Patients in cardiogenic shock

          -  Acute myocardial infarction (MI) within the past 72 hours, and/or elevated CPK (and
             abnormal Troponin-I) at the time of enrollment

          -  Patients with a life expectancy of less than 1 year

          -  Target main branch vessel &lt; 2.5 mm in diameter

          -  Target main branch lesion &gt; 30 mm in length

          -  Intended use of a bare metal stent (BMS) in the main branch

          -  Target side branch vessel &lt; 2.0 mm in diameter

          -  Target side branch lesion &gt; 15 mm in length

          -  Target bifurcation angle &gt; 90º (distal angle)

          -  Totally obstructed target coronary arteries (TIMI 0 or 1 flow)

          -  Target bifurcation lesion within a previously placed stent (i.e. in-stent restenosis
             (ISR))

          -  Target bifurcation lesion within a surgical conduit (e.g. saphenous vein or internal
             mammary)

          -  Target lesion demonstrating severe dissection prior to planned deployment of the
             AngioSculpt device

          -  Unprotected Left Main diameter stenosis ≥ 50%

          -  Visible thrombus (by angiography) at target lesion site

          -  Coronary spasm in the absence of a significant stenosis

          -  Patients who are concurrently participating in an investigational study when such
             participation could confound the treatment or outcomes of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey W. Moses, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <results_first_submitted>June 17, 2011</results_first_submitted>
  <results_first_submitted_qc>July 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2011</results_first_posted>
  <last_update_submitted>July 14, 2011</last_update_submitted>
  <last_update_submitted_qc>July 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Gary Gershony, M.D., Chief Medical Officer</name_title>
    <organization>AngioScore, Inc.</organization>
  </responsible_party>
  <keyword>Coronary Angioplasty</keyword>
  <keyword>Coronary Stents</keyword>
  <keyword>Scoring Balloons</keyword>
  <keyword>Coronary Artery Bifurcation Lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AngioSculpt Device</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AngioSculpt Device</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.54" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Procedural Success</title>
        <description>Defined as less than or equal to 30% diameter stenosis in the main branch and less than or equal to 70% diameter stenosis in the side branch at the conclusion of the procedure (including adjunctive stenting) in the absence of in-hospital major adverse cardiac events (MACE) [cardiac death, myocardial infarction (MI), or target lesion revascularization (TLR]</description>
        <time_frame>1 day</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>Defined as less than or equal to 30% diameter stenosis in the main branch and less than or equal to 70% diameter stenosis in the side branch at the conclusion of the procedure (including adjunctive stenting) in the absence of in-hospital major adverse cardiac events (MACE) [cardiac death, myocardial infarction (MI), or target lesion revascularization (TLR]</description>
          <population>intention to treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiovascular Events</title>
        <description>cardiac death, myocardial infarction, or target lesion revascularization</description>
        <time_frame>30 days</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>AngioSculpt Device</title>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiovascular Events</title>
          <description>cardiac death, myocardial infarction, or target lesion revascularization</description>
          <population>intention to treat</population>
          <units>percentage of particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac Events</title>
        <description>cardiac death, myocardial infarction, or target lesion revascularization</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AngioSculpt Device</title>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Events</title>
          <description>cardiac death, myocardial infarction, or target lesion revascularization</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AngioSculpt Device</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Investigator felt that patient death was due to arrythmia and not study related.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to submission, the Sponsor, Institution, and Site Investigators will review and authorize the publication. A review period of 15 days for Presentational materials and abstracts; and 30 days for manuscripts is required for the Sponsor's review. Sponsor review does not include editorial privileges but can protect proprietary information and correct errors in data reporting or analysis if the Investigator agrees that there is an error.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gary Gershony, MD/ Chief Medical Officer</name_or_title>
      <organization>AngioScore</organization>
      <phone>510-933-7900</phone>
      <email>gary@angioscore.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

